Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
97.00    1.60 (1.68%)
Bid:
96.10
Ask:
97.30
Spread: 1.20 (1.249%)
Market Cap: £589.95m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Directorate Change

31 Dec 2021 07:00

RNS Number : 6395W
Syncona Limited
31 December 2021
 

Syncona Limited

 

Directorate Change

 

31 December 2021

 

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, notes that as previously announced, Nigel Keen and Nicholas Moss step down as Non-Executive Directors on 31 December 2021.

 

Virginia Holmes will become Senior Independent Director and Gian Piero Reverberi will become Chair of the Remuneration Committee, in each case from 1 January 2022.

 

[ENDS]

 

Enquiries

 

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 7714 916615

 

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

Company Secretary

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758228

 

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.

 

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFELFSDEFSEEE
Date   Source Headline
21st Jun 20194:18 pmRNSDirector Information
13th Jun 20192:27 pmRNSDividend Announcement
13th Jun 20197:00 amRNSAnnual Financial Report
4th Jun 20197:00 amRNSAppointment of Chair-Designate and NED
20th May 20197:00 amRNSSyncona founds Quell with £35m Series A Financing
14th May 201912:00 pmRNSAutolus reports Q1 2019 Financial Results
7th May 20197:00 amRNSBED announces initial clinical experience of PSMA
16th Apr 20197:00 amRNSAutolus announces closing of public offering
11th Apr 20197:09 amRNSAutolus announces pricing of public offering
11th Apr 20197:00 amRNSCreation of leading retinal gene therapy platform
9th Apr 20197:00 amRNSAutolus announces launch of proposed offering
1st Apr 20196:14 pmRNSAutolus presents initial AUTO1 adult ALL data
27th Mar 201911:12 amRNSDirector/PDMR Shareholding
26th Mar 201910:18 amRNSAutolus hosts R&D day and updates on AUTO3
20th Mar 20194:27 pmRNSDirector/PDMRs Shareholding
19th Mar 20195:48 pmRNSStandard form for notification of major holdings
19th Mar 20194:44 pmRNSDirectors/PDMR Shareholdings
18th Mar 20194:15 pmRNSNotification of Major Holdings
13th Mar 20194:55 pmRNSResults of Placing in Syncona Limited
13th Mar 20197:00 amRNSProposed Placing in Syncona Limited
12th Mar 20197:00 amRNSUpdate on management of strategic capital pool
4th Mar 20197:11 amRNSNightstar agreement to be acquired by Biogen
26th Feb 20197:00 amRNSSyncona leads CHF 35 million financing in Anaveon
19th Feb 201911:52 amRNSAutolus announces Results from CARPALL Trial
13th Feb 20197:00 amRNSQuarterly Update
16th Jan 20197:00 amRNSAppointment of Joint Corporate Broker
17th Dec 201812:38 pmRNSChange of Registered Office - Released in Error
17th Dec 201811:47 amRNSChange of Registered Office
4th Dec 20187:00 amRNSFreeline presents data at the ASH Annual Meeting
3rd Dec 20187:00 amRNSAutolus announces update on AUTO4 and AUTO5
3rd Dec 20187:00 amRNSAutolus presents AUTO3 data at ASH Annual Meeting
26th Nov 20189:57 amRNSAutolus publishes Annual Report
21st Nov 20187:10 amRNSInterim Results
13th Nov 20187:00 amRNSNightstar reports Q3 2018 financial results
1st Nov 20181:40 pmRNSAutolus Therapeutics to Present New Data at ASH
1st Nov 20181:36 pmRNSFreeline releases initial data for FLT180a
1st Nov 20187:00 amRNSDirector Information
30th Oct 201811:24 amRNSResult of Extraordinary General Meeting
4th Oct 20187:00 amRNSPublication of EGM Circular
3rd Oct 20187:00 amRNSNightstar closes public offering
28th Sep 20187:00 amRNSNightstar announces pricing of public offering
24th Sep 20187:00 amRNSNightstar reports positive proof of concept data
3rd Sep 201811:22 amRNSChange of Administrator and Depositary
31st Aug 20184:08 pmPRNTotal Voting Rights
13th Aug 201812:39 pmPRNIssue of shares pursuant to the Long Term Incentive Plan
13th Aug 201811:11 amPRNNightstar reports Q2 2018 financial results
9th Aug 20187:00 amPRNSyncona Limited Quarterly Update
2nd Aug 20184:49 pmPRNPDMR Dealing
31st Jul 20182:21 pmPRNResults of AGM
31st Jul 20187:00 amPRNTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.